Nanostring intends to price $55 million public sale of common stock

Funds used to commercialize and expand clinical utility of Prosigna

By Devika Patel

Knoxville, Tenn., Jan. 21 - Nanostring Technologies, Inc. said it will price a $55 million public offering of common stock with an $8.25 million greenshoe.

J.P. Morgan and Morgan Stanley are the bookrunners. Leerink Partners and Robert W. Baird & Co. Inc. are the co-managers.

Proceeds will be used to commercialize Prosigna, expand the clinical utility of Prosigna and develop other diagnostic product opportunities, expand life sciences commercial operations, develop new life sciences applications, chemistry and instrumentation for the nCounter technology platform and for working capital and other general corporate purposes.

The Seattle company develops and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.